Search: WFRF:(Mateo I.)
> (2020-2024) >
Real-world biologic...
Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan
-
- Miyazaki, Celine (author)
- Value, Evidence and Access Department, Janssen Pharmaceutical K.K., Tokyo, Japan
-
- Masuda, Junya (author)
- Medical Affairs Division, Immunology and Infectious Disease Department, Janssen Pharmaceutical K.K., Tokyo, Japan
-
- Rodriguez-Rey, Mateo Delclaux (author)
- Parexel International, London, United Kingdom
-
show more...
-
- Stelmaszuk, Marta Natalia (author)
- Parexel International, Stockholm, Sweden
-
- Freilich, Jonatan (author)
- Umeå universitet,Institutionen för folkhälsa och klinisk medicin,Parexel International, Stockholm, Sweden
-
- Tsai, Phiona I-Ching (author)
- Value, Evidence and Access Department, Janssen Pharmaceutical K.K., Tokyo, Japan
-
- Saeki, Hidehisa (author)
- Department of Dermatology, Nippon Medical School, Tokyo, Japan
-
show less...
-
Value, Evidence and Access Department, Janssen Pharmaceutical KK., Tokyo, Japan Medical Affairs Division, Immunology and Infectious Disease Department, Janssen Pharmaceutical K.K., Tokyo, Japan (creator_code:org_t)
- Taylor & Francis, 2024
- 2024
- English.
-
In: Journal of dermatological treatment (Print). - : Taylor & Francis. - 0954-6634 .- 1471-1753. ; 35:1
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: With advent of newer treatments for psoriasis, real-world use of biologics in Japan is evolving.Methods: This retrospective study utilized data from patients with ≥1 psoriasis-related biologic claims record between January 2016 and December 2020 in Japan to evaluate treatment patterns, healthcare resource utilization (HCRU), and associated costs. Data were analyzed using descriptive statistics.Results: Of 1,614 eligible patients, 72.5% were male, 29.2% had comorbid hypertension and 26.6% had comorbid cardiovascular disease. Interleukin (IL)-17 and tumor necrosis factor alpha (TNFα) inhibitors were commonly prescribed across lines of treatment, while IL-23 inhibitors were most considered for switches (92% of switches were from IL-12/23/IL-17/TNFα inhibitors). The overall mean adherence rate for all classes was 80.1%, but adherence varied across biologics. Infliximab and IL-23 inhibitor users exhibited optimal medical possession ratios, reflecting the best adherence rates. Overall HCRU (visits/patient-year) was 9.05 for outpatient visits, 0.09 for inpatient hospitalization, and 0.5 for psoriasis-related phototherapy. HCRU associated with hospitalization was slightly higher for bio-experienced patients and so was the overall costs per patient-year relative to bio-naïve patients.Conclusion: Variable adherence rates observed suggest the need for improvement in treatment management with different biologics. Bio-experienced patients burdened by disease progression and treatment switches may result in increased HCRU.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Keyword
- Biologics
- healthcare resource utilization
- psoriasis
- treatment pattern
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database